文献速递临床试验与 GCP流行病学与生物统计

小样本序贯多阶段随机试验中贝叶斯方法比较剂量水平与安慰剂

Bayesian methods to compare dose levels with placebo in a small n, sequential, multiple assignment, randomized trial.
PubMed 文献 · Stat Med · 2020-11-20

针对罕见病试验患者有限的问题,提出一种小样本序贯多阶段随机试验(snSMART)设计,比较药物低剂量和高剂量与安慰剂的应答率。采用贝叶斯方法借入两阶段信息,并与仅用第一阶段数据及对数线性泊松模型比较,结果显示贝叶斯方法的均方根误差和95%可信区间宽度更小。

要点

  • 贝叶斯方法利用两阶段数据,均方根误差和95%可信区间宽度小于标准方法。
  • 该snSMART设计可用于罕见病药物注册。
  • 建议主要疗效分析纳入两阶段数据。

核心结论

  • 利用两阶段数据进行主要疗效分析具有优势。
  • 所提出的snSMART设计可用于罕见病药物注册。
  • 贝叶斯方法在测试场景下均方根误差和95%可信区间宽度小于标准方法。

研究设计与样本

  • 提出一种snSMART设计,研究药物低剂量和高剂量与安慰剂的应答率。
  • 患者随机分配至初始治疗(第一阶段)。
  • 第二阶段根据初始治疗及第一阶段应答重新随机分配至相同或不同剂量。
  • 采用贝叶斯方法在第一阶段和第二阶段之间借入信息。

主要发现

  • 贝叶斯方法的均方根误差和95%可信区间宽度小于仅用第一阶段数据的标准方法。
  • 贝叶斯方法的均方根误差和95%可信区间宽度小于使用两阶段数据的对数线性泊松模型(参数用广义估计方程估计)。

临床怎么用

  • 在罕见病药物试验中可考虑采用该snSMART设计。
  • 主要疗效分析应纳入两阶段数据。
  • 贝叶斯方法可用于比较低剂量和高剂量与安慰剂的应答率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials studying treatments for rare diseases are challenging to design and conduct due to the limited number of patients eligible for the trial. One design used to address this challenge is the small n, sequential, multiple assignment, randomized trial (snSMART). We propose a new snSMART design that investigates the response rates of a drug tested at a low and high dose compared with placebo. Patients are randomized to an initial treatment (stage 1). In stage 2, patients are rerandomized, depending on their initial treatment and their response to that treatment in stage 1, to either the same or a different dose of treatment. Data from both stages are used to determine the efficacy of the active treatment. We present a Bayesian approach where information is borrowed between stage 1 and stage 2. We compare our approach to standard methods using only stage 1 data and a log-linear Poisson model that uses data from both stages where parameters are estimated using generalized estimating equations. We observe that the Bayesian method has smaller root-mean-square-error and 95% credible interval widths than standard methods in the tested scenarios. We conclude that it is advantageous to utilize data from both stages for a primary efficacy analysis and that the specific snSMART design shown here can be used in the registration of a drug for the treatment of rare diseases.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Fang F, Hochstedler KA, Tamura RN, et al. Bayesian methods to compare dose levels with placebo in a small n, sequential, multiple assignment, randomized trial. Stat Med. 2020. PMID: 33216360. doi:10.1002/sim.8813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。